A * STAR researchers have provided strong evidence using grafts of tumor patients that of metformin, a common diabetes drug may help fight colon cancer.
Treatment of colorectal cancer in Israel in a leading private clinic Assuta from the best Israeli oncologists.
In preclinical studies it has demonstrated the potential of Metformin as an agent that suppresses tumor, to prevent the growth of breast, colon, lung and prostate. However, the experimental models used in these studies do not accurately recreate the natural manifestations of the disease and require toxic levels of metformin to demonstrate the beneficial effects.
Min-Han Tan and a team of researchers from the Institute of Bioengineering and Nanotechnology (IBN) A * STAR, the Biological Resource Center and Singapore's Genome Institute, in collaboration with hospitals in Singapore are now tested the ability of the fight with the help of metformin in a model of colorectal cancer, which is more typical for as the disease appears in humans.
Command cancerous tissue samples taken from two patients and their implanted in mice, and then evaluated as tumors responded to metformin and 5-fluorouracil, current treatment of colon cancer.
They found that metformin inhibited tumor growth by at least 50% after 24 days and, in combination with 5-FU inhibited tumor grafts in one patient of 85%. In the experiments, metformin concentrations equivalent to those for the treatment of diabetes in humans.
In previous studies, researchers usually injected cancer cells in animals, rather than directly transplanted tissue. In these models, the levels of glucose, insulin, and growth factor necessary for establishing cell cultures for injection. Group Tan suspects that the built environment has meant that previous studies have demanded higher levels of metformin to stop tumor growth, as in this study, they were able to demonstrate a response to the use of therapeutic doses of the drug: "We have tested a wide range of concentrations up to a physiological, - says Tan . "It was important to show that at this level was the answer, as many studies have not detected it."
Under the leadership of IBN, it was found that metformin applied their therapeutic benefits, activating cellular pathway involved in the inhibition of cancer, and by reducing the consumption of oxygen in cancer cells. Using genetic sequencing of the next generation, the team has also provided evidence that direct tissue grafts in mice retain the genetic, molecular and tissue features of the original tumor, making them ideal platforms for the study of colorectal cancer and its treatment.
It is believed that this is the first study of the effect of metformin on colorectal cancer using tumor transplant patients. Tan said that future research may shed light on the relevance of metformin as a therapeutic agent for the treatment of cancer: "Our research shows that metformin has a potential activity against colorectal cancer, using material from the gold standard, and provides a mechanism to explain this, it is now necessary."
Source: Molecular Cancer Therapeutics